本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Viking Therapeutics, Inc.

41.00
+0.40000.99%
成交量:496.13万
成交额:2.05亿
市值:46.34亿
市盈率:-19.34
高:43.15
开:42.09
低:40.01
收:40.60
52周最高:62.50
52周最低:18.92
股本:1.13亿
流通股本:1.10亿
量比:1.11
换手率:4.51%
股息:- -
股息率:- -
每股收益(TTM):-2.1195
每股收益(LYR):-1.0085
净资产收益率:-29.23%
总资产收益率:-20.48%
市净率:6.50
市盈率(LYR):-40.65

数据加载中...

2024/04/25

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/04/24

重要事件披露

Form 8-K - Current report
2024/03/26

重要事件披露

Form 8-K - Current report
2024/03/04

重要事件披露

Form 8-K - Current report
2024/03/01

重要事件披露

Form 8-K - Current report
2024/02/27

重要事件披露

Form 8-K - Current report
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/09

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/09

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/09

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/07

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/02/07

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/02/07

重要事件披露

Form 8-K - Current report
2024/02/01

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/01/31

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/01/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/01/13

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/01/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/11/02

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals